Dinesh Raghu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dinesh Raghu has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Ygal Haupt
Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
6 shared publications - Cristina Gamell
Departament de Ciències Fisiològiques II, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Spain
4 shared publications - Devarajan Karunagaran
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, India
3 shared publications - Lisa Anna Mielke
Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Australia
3 shared publications - Stephen BSc(Hons) Fox
Affiliations Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
3 shared publications Sue Haupt
From the ‡The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
3 shared publications
Latest Publications
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (88) , eadf2163
TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma
Intraepithelial lymphocytes (IELs), including αβ and γδ T cells (T-IELs), constantly survey and play a critical role in maintaining the gastrointestinal epithelium. We show that cytotoxic molecules important for defense against cancer were highly expressed by T-IELs in the small intestine. In contrast, abundance of colonic T-IELs was dependent on the microbiome and displayed higher expression of TCF-1/ TCF7 and a reduced effector and cytotoxic profile, including low expression of granzymes. Targeted deletion of TCF-1 in γδ T-IELs induced a distinct effector profile and reduced colon tumor formation in mice. In addition, TCF-1 expression was significantly reduced in γδ T-IELs present in human colorectal cancers (CRCs) compared with normal healthy colon, which strongly correlated with an enhanced γδ T-IEL effector phenotype and improved patient survival. Our work identifies TCF-1 as a colon-specific T-IEL transcriptional regulator that could inform new immunotherapy strategies to treat CRC.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (88) , eadf2163
TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma
Intraepithelial lymphocytes (IELs), including αβ and γδ T cells (T-IELs), constantly survey and play a critical role in maintaining the gastrointestinal epithelium. We show that cytotoxic molecules important for defense against cancer were highly expressed by T-IELs in the small intestine. In contrast, abundance of colonic T-IELs was dependent on the microbiome and displayed higher expression of TCF-1/ TCF7 and a reduced effector and cytotoxic profile, including low expression of granzymes. Targeted deletion of TCF-1 in γδ T-IELs induced a distinct effector profile and reduced colon tumor formation in mice. In addition, TCF-1 expression was significantly reduced in γδ T-IELs present in human colorectal cancers (CRCs) compared with normal healthy colon, which strongly correlated with an enhanced γδ T-IEL effector phenotype and improved patient survival. Our work identifies TCF-1 as a colon-specific T-IEL transcriptional regulator that could inform new immunotherapy strategies to treat CRC.
- 1 December 2019
- Published by Elsevier in Trends in Immunology
- Vol. 40 (12) , 1149-1162
Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1
- 1 December 2019
- Published by Elsevier in Trends in Immunology
- Vol. 40 (12) , 1149-1162
Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1
- Open Access
- 29 May 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (7) , 1682-1699
TCF-1 limits the formation of Tc17 cells via repression of the MAF–RORγt axis
Interleukin (IL)-17–producing CD8+ T (Tc17) cells have emerged as key players in host-microbiota interactions, infection, and cancer. The factors that drive their development, in contrast to interferon (IFN)-γ–producing effector CD8+ T cells, are not clear. Here we demonstrate that the transcription factor TCF-1 (Tcf7) regulates CD8+ T cell fate decisions in double-positive (DP) thymocytes through the sequential suppression of MAF and RORγt, in parallel with TCF-1–driven modulation of chromatin state. Ablation of TCF-1 resulted in enhanced Tc17 cell development and exposed a gene set signature to drive tissue repair and lipid metabolism, which was distinct from other CD8+ T cell subsets. IL-17–producing CD8+ T cells isolated from healthy humans were also distinct from CD8+IL-17− T cells and enriched in pathways driven by MAF and RORγt. Overall, our study reveals how TCF-1 exerts central control of T cell differentiation in the thymus by normally repressing Tc17 differentiation and promoting an effector fate outcome.
- 29 May 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (7) , 1682-1699
Open AccessTCF-1 limits the formation of Tc17 cells via repression of the MAF–RORγt axis
Interleukin (IL)-17–producing CD8+ T (Tc17) cells have emerged as key players in host-microbiota interactions, infection, and cancer. The factors that drive their development, in contrast to interferon (IFN)-γ–producing effector CD8+ T cells, are not clear. Here we demonstrate that the transcription factor TCF-1 (Tcf7) regulates CD8+ T cell fate decisions in double-positive (DP) thymocytes through the sequential suppression of MAF and RORγt, in parallel with TCF-1–driven modulation of chromatin state. Ablation of TCF-1 resulted in enhanced Tc17 cell development and exposed a gene set signature to drive tissue repair and lipid metabolism, which was distinct from other CD8+ T cell subsets. IL-17–producing CD8+ T cells isolated from healthy humans were also distinct from CD8+IL-17− T cells and enriched in pathways driven by MAF and RORγt. Overall, our study reveals how TCF-1 exerts central control of T cell differentiation in the thymus by normally repressing Tc17 differentiation and promoting an effector fate outcome.
- Open Access
- 1 June 2018
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 17 (6) , 1170-1183
Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells
- 1 June 2018
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 17 (6) , 1170-1183
Open AccessProteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells
- Open Access
- 19 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (26) , 42939-42948
E6AP promotes prostate cancer by reducing p27 expression
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Dinesh Raghu1, 2, Piotr Jan Paul1, 2, Twishi Gulati1, 2, Siddhartha Deb3, Christine Khoo4, Andrea Russo5, Enzo Gallo5, Giovanni Blandino6, Ai-Leen Chan2, 11, Elena Takano4, Shahneen K. Sandhu7, Stephen B. Fox4, Scott Williams8, Sue Haupt1, 2, Cristina Gamell1, 2, * and Ygal Haupt1, 2, 9, 10, * 1The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia 2Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 3Anatpath Services Pty Ltd, Gardenvale, Victoria, Australia 4Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 5Department of Surgical Pathology, Regina Elena Cancer Institute, Rome, Italy 6Oncogenomic and Epigenetic Unit, Italian National Cancer Institute, Rome, Italy 7Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 8Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 9Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia 10Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia 11Current address: Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia *Both authors have shared co-senior authorship Correspondence to: Ygal Haupt, email: ygal.haupt@petermac.org Keywords: prostate cancer, E6AP, p27, E2F1, tumor suppression Received: February 07, 2017 Accepted: March 16, 2017 Published: April 19, 2017 ABSTRACT Prostate cancer (PC) is the most common cancer in men. Elevated levels of E3 ligase, E6-Associated Protein (E6AP) were previously linked to PC, consistent with increased protein expression in a subset of PC patients. In cancers, irregular E3 ligase activity drives proteasomal degradation of tumor suppressor proteins. Accordingly, E3 ligase inhibitors define a rational therapy to restore tumor suppression. The relevant tumor suppressors targeted by E6AP in PC are yet to be fully identified. In this study we show that p27, a key cell cycle regulator, is a target of E6AP in PC. Down regulation of E6AP increases p27 expression and enhances its nuclear accumulation in PC. We demonstrate that E6AP regulates p27 expression by inhibiting its transcription in an E2F1-dependent manner. Concomitant knockdown of E6AP and p27 partially restores PC cell growth, supporting the contribution of p27 to the overall effect of E6AP on prostate tumorigenesis. Overall, we unravelled the E6AP-p27 axis as a new promoter of PC, exposing an attractive target for therapy through the restoration of tumor suppression.
- 19 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (26) , 42939-42948
Open AccessE6AP promotes prostate cancer by reducing p27 expression
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Dinesh Raghu1, 2, Piotr Jan Paul1, 2, Twishi Gulati1, 2, Siddhartha Deb3, Christine Khoo4, Andrea Russo5, Enzo Gallo5, Giovanni Blandino6, Ai-Leen Chan2, 11, Elena Takano4, Shahneen K. Sandhu7, Stephen B. Fox4, Scott Williams8, Sue Haupt1, 2, Cristina Gamell1, 2, * and Ygal Haupt1, 2, 9, 10, * 1The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia 2Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 3Anatpath Services Pty Ltd, Gardenvale, Victoria, Australia 4Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 5Department of Surgical Pathology, Regina Elena Cancer Institute, Rome, Italy 6Oncogenomic and Epigenetic Unit, Italian National Cancer Institute, Rome, Italy 7Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 8Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 9Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia 10Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia 11Current address: Australian Regenerative Medicine Institute, Monash University, Melbourne, Victoria, Australia *Both authors have shared co-senior authorship Correspondence to: Ygal Haupt, email: ygal.haupt@petermac.org Keywords: prostate cancer, E6AP, p27, E2F1, tumor suppression Received: February 07, 2017 Accepted: March 16, 2017 Published: April 19, 2017 ABSTRACT Prostate cancer (PC) is the most common cancer in men. Elevated levels of E3 ligase, E6-Associated Protein (E6AP) were previously linked to PC, consistent with increased protein expression in a subset of PC patients. In cancers, irregular E3 ligase activity drives proteasomal degradation of tumor suppressor proteins. Accordingly, E3 ligase inhibitors define a rational therapy to restore tumor suppression. The relevant tumor suppressors targeted by E6AP in PC are yet to be fully identified. In this study we show that p27, a key cell cycle regulator, is a target of E6AP in PC. Down regulation of E6AP increases p27 expression and enhances its nuclear accumulation in PC. We demonstrate that E6AP regulates p27 expression by inhibiting its transcription in an E2F1-dependent manner. Concomitant knockdown of E6AP and p27 partially restores PC cell growth, supporting the contribution of p27 to the overall effect of E6AP on prostate tumorigenesis. Overall, we unravelled the E6AP-p27 axis as a new promoter of PC, exposing an attractive target for therapy through the restoration of tumor suppression.
- 18 January 2017
- Published by Wiley in The Journal of Pathology
- Vol. 241 (5) , 661-670
MDM4 is a rational target for treating breast cancers with mutant p53
Mutation of the key tumour suppressor p53 defines a transition in the progression towards aggressive and metastatic breast cancer (BC) with the poorest outcome. Specifically, the p53 mutation frequency exceeds 50% in triple‐negative BC. Key regulators of mutant p53 that facilitate its oncogenic functions are potential therapeutic targets. We report here that the MDM4 protein is frequently abundant in the context of mutant p53 in basal‐like BC samples. Importantly, we show that MDM4 plays a critical role in the proliferation of these BC cells. We demonstrate that conditional knockdown (KD) of MDM4 provokes growth inhibition across a range of BC subtypes with mutant p53, including luminal, Her2+ and triple‐negative BCs. In vivo, MDM4 was shown to be crucial for the establishment and progression of tumours. This growth inhibition was mediated, at least in part, by the cell cycle inhibitor p27. Depletion of p27 together with MDM4 KD led to recovery of the proliferative capacity of cells that were growth‐inhibited by MDM4 KD alone. Consistently, we identified low levels of p27 expression in basal‐like tumours corresponding to high levels of MDM4 and p53. This predicts a signature for a subset of tumours that may be amenable to therapies targeted towards MDM4 and mutant p53. The therapeutic potential of MDM4 as a target in BC with mutant p53 was shown in vitro by use of a small‐molecule inhibitor. Overall, our study supports MDM4 as a novel therapeutic target for BC expressing mutant p53. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 18 January 2017
- Published by Wiley in The Journal of Pathology
- Vol. 241 (5) , 661-670
MDM4 is a rational target for treating breast cancers with mutant p53
Mutation of the key tumour suppressor p53 defines a transition in the progression towards aggressive and metastatic breast cancer (BC) with the poorest outcome. Specifically, the p53 mutation frequency exceeds 50% in triple‐negative BC. Key regulators of mutant p53 that facilitate its oncogenic functions are potential therapeutic targets. We report here that the MDM4 protein is frequently abundant in the context of mutant p53 in basal‐like BC samples. Importantly, we show that MDM4 plays a critical role in the proliferation of these BC cells. We demonstrate that conditional knockdown (KD) of MDM4 provokes growth inhibition across a range of BC subtypes with mutant p53, including luminal, Her2+ and triple‐negative BCs. In vivo, MDM4 was shown to be crucial for the establishment and progression of tumours. This growth inhibition was mediated, at least in part, by the cell cycle inhibitor p27. Depletion of p27 together with MDM4 KD led to recovery of the proliferative capacity of cells that were growth‐inhibited by MDM4 KD alone. Consistently, we identified low levels of p27 expression in basal‐like tumours corresponding to high levels of MDM4 and p53. This predicts a signature for a subset of tumours that may be amenable to therapies targeted towards MDM4 and mutant p53. The therapeutic potential of MDM4 as a target in BC with mutant p53 was shown in vitro by use of a small‐molecule inhibitor. Overall, our study supports MDM4 as a novel therapeutic target for BC expressing mutant p53. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 19 September 2016
- Published by Springer Nature in Oncogene
- Vol. 35 (48) , 6235-6245
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP
Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP–PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.
- 19 September 2016
- Published by Springer Nature in Oncogene
- Vol. 35 (48) , 6235-6245
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP
Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP–PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.
- Open Access
- 27 January 2016
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 12
Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways
The tumour suppressor p53 normally acts as a brake to halt damaged cells from perpetrating their genetic errors into future generations. If p53 is disrupted by mutation, it may not only lose these corrective powers, but counter-productively acquire new capacities that drive cancer. A newly emerging manner in which mutant p53 executes its cancer promoting functions is by harnessing key proteins (including many transcription factors), which normally partner with its wild type, tumour-inhibiting counterpart. In association with the subverted activities of these protein partners, mutant p53 is empowered to act across multiple fundamental cellular pathways (regulating cell division and metabolism) and corrupt them to become cancer promoting.
- 27 January 2016
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 12
Open AccessMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways
The tumour suppressor p53 normally acts as a brake to halt damaged cells from perpetrating their genetic errors into future generations. If p53 is disrupted by mutation, it may not only lose these corrective powers, but counter-productively acquire new capacities that drive cancer. A newly emerging manner in which mutant p53 executes its cancer promoting functions is by harnessing key proteins (including many transcription factors), which normally partner with its wild type, tumour-inhibiting counterpart. In association with the subverted activities of these protein partners, mutant p53 is empowered to act across multiple fundamental cellular pathways (regulating cell division and metabolism) and corrupt them to become cancer promoting.
- Open Access
- 10 March 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 57
p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress
P53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress
- 10 March 2015
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 57
Open Accessp53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress
P53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (15) , 3647-3651
Synthesis and SAR study of novel anticancer and antimicrobial naphthoquinone amide derivatives
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (15) , 3647-3651
Synthesis and SAR study of novel anticancer and antimicrobial naphthoquinone amide derivatives